Results 181 to 190 of about 126,887 (307)

YBX1&YBX3 as novel targets to potentiate immune checkpoint blockade response in gliomas. [PDF]

Neuro Oncol
Ali H, Zhou N, Chen L, van Hijfte L, Tulaiha R, Karri V, Zhou Y, Habashy K, Arrieta VA, Kim KS, Duffy J, Yeeravalli R, Tiek DM, Song X, Mishra S, Horbinski C, Lee-Chang C, Ahmed A, Wang L, Heiland DH, Sonabend AM, Dmello C.   +21 more
europepmc   +1 more source

Immune Checkpoint Blockade in Hepatocellular Carcinoma [PDF]

Liver Cancer, 2015
openaire   +2 more sources

DMAP1 Deficiency Suppresses Lung Cancer Progression by Destabilizing Replication Fork and Activating IFN Signaling‐Mediated Anti‐tumor Immunity

Advanced Science, EarlyView.
Lung cancer remains the leading cause of cancer‐related death. We investigated the role of the epigenetic regulator DMAP1 in NSCLC and found that its loss induces replication stress and DNA damage. This in turn activates type I IFN signaling via the cGAS–STING pathway and transcriptional ISG de‐repression, enhancing anti‐tumor immune responses ...
Kan Huang, Xi Dai, Shuaihu Li, Yingxue Chen, Yaxin Yu, Lin Wang, Kun Liu, Shuhan Lyu, Chongyang Li, Yihua Sun, Fei Li   +10 more
wiley   +1 more source

Engineered Bacteria Factory Integrating Drug Delivery and Antibody Manufacture for Activating the STING Signal Pathway Mediated Tumor Immunotherapy

Advanced Science, EarlyView.
To address the limitations of protein‐based ICIs in applications, this study constructed an engineered bacterium, HRB, capable of expressing aCD47 in hypoxic TME. Through the Schiff base reaction, responsive liposomes (LC) loaded with the STING agonist cGAMP were connected to the surface of bacteria to form HRB@LC.
Peng‐Shuo Dong, Tian Yao, Yong Li, Zi‐Hui Yan, Xiao‐Ting Xie, Jia‐Hua Zou, Kai Cheng, Jin‐Xuan Fan, Yuan‐Di Zhao, Qiu‐Ran Xu   +9 more
wiley   +1 more source

Merkel cell carcinoma immunotherapy: key questions in the era of immune checkpoint blockade. [PDF]

J Immunother Cancer
Becker JC, Lodde G, Haist M, Ugurel S.
europepmc   +1 more source

Cancer immunogenomics: Computational neoantigen identification and vaccine design [PDF]

, 2016
Coffman, Adam, Graubert, Aaron, Griffith, Malachi, Griffith, Obi L, Hundal, Jasreet, Kiwala, Susanna, Mardis, Elaine R, McMichael, Joshua, Miller, Christopher J, Walker, Jason   +9 more
core   +2 more sources

A Radioresistant‐Tumor‐Targeted Nanoparticle for X‐Ray‐Controlled Nitric Oxide Release to Potentiate Radiotherapy

Advanced Science, EarlyView.
The PBTN targets GRP78 and, upon X‐ray irradiation, generates ONOO− to induce immunogenic cell death, thereby activating CD8+ T cells and establishing a systemic antitumor immune response. ABSTRACT Nitric oxide (NO) treated radioresistant tumors by relieving hypoxia and blocking DNA repair, but its nonselective toxicity has precluded therapeutic use ...
Wanze Zhang, Xiaoyan Yin, Ting Wang, Hongfu Zhao, Zhipeng Zhao, Jinbao Wang, Cheng Tao, Xuanchu Ge, Yanze Li, Linlin Liu, Fuxin Xue   +10 more
wiley   +1 more source

Dual Targeting of HIF-1α and DLL4 by Isoxanthohumol Potentiates Immune Checkpoint Blockade. [PDF]

Int J Mol Sci
Kim D, You J, Bae SH, Jeong JH, Jung JH, Kim JA, Lee YM.   +6 more
europepmc   +1 more source

The AUTACE That Degrades KRAS and Engages CD8+ T Cells for the Treatment of KRAS/TP53 Co‐Mutant Tumors

Advanced Science, EarlyView.
AUTACE is a bifunctional nanoplatform that integrates tumor targeting, immune engagement, and on‐demand KRAS degradation. It targets KRAS/TP53 co‐mutant tumors via TP53‐specific TCRs, elicits antitumor CD8+ T‐cell responses through surface anti‐CD3 antibodies, and uses low‐intensity focused ultrasound (LIFU) to trigger controlled release of the KRAS ...
Luo Li, Bolin Li, Yanan Hao, Bo Pang, Pan Li, Chunli Li, Yu Tang   +6 more
wiley   +1 more source

Evidence of Cardiotoxic Immune Activation by Triple Immune Checkpoint Blockade: A Translational Alert for Clinical Surveillance in Patients With Cancer. [PDF]

J Cardiovasc Pharmacol
Quagliariello V, Passariello M, Belardo M, Esposito A, Paone M, Berretta M, Iovine M, Barbato M, Canale ML, Paccone A, Inno A, Oliva S, Maurea C, Forte P, Mauriello A, Fonderico C, Gallucci G, Tarantini L, Camilli M, Camerini A, De Lorenzo C, Maurea N.   +21 more
europepmc   +1 more source